.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Baxter
Queensland Health
Federal Trade Commission
Merck
Daiichi Sankyo
McKinsey
Harvard Business School
Covington

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,900,221

« Back to Dashboard

Which drugs does patent 6,900,221 protect, and when does it expire?


Patent 6,900,221 protects TARCEVA and is included in one NDA. There has been one Paragraph IV challenge on Tarceva.

Protection for TARCEVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-three patent family members in thirty-seven countries.

Summary for Patent: 6,900,221

Title: Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
Abstract:The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
Inventor(s): Norris; Timothy (Gales Ferry, CT), Raggon; Jeffrey W. (North Stonington, CT), Connell; Richard D. (East Lyme, CT), Moyer; James D. (East Lyme, CT), Morin; Michael J. (Waterford, CT), Kajiji; Shama M. (Mystic, CT), Foster; Barbara A. (Mystic, CT), Ferrante; Karen J. (East Greenwich, RI), Silberman; Sandra L. (Randolph, NJ)
Assignee: OSI Pharmaceuticals, Inc. (Melville, NY)
Application Number:09/711,272
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-001Nov 18, 2004RXYesNo6,900,221*PED► SubscribeY
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-002Nov 18, 2004RXYesNo6,900,221*PED► SubscribeY
Osi Pharms
TARCEVA
erlotinib hydrochloride
TABLET;ORAL021743-003Nov 18, 2004RXYesYes6,900,221*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,900,221

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,087,613Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,900,221

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland223486► Subscribe
Poland355235► Subscribe
New Zealand518406► Subscribe
Norway327082► Subscribe
Norway20021910► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Queensland Health
Baxter
Citi
Chubb
Chinese Patent Office
Covington
Johnson and Johnson
UBS
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot